WORCESTER, Mass., June 21, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical...
WORCESTER, Mass., June 20, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical...
Overall response rate of 90% in cohort with durable responses observed; one patient remains in complete remission at 31 months All patients were heavily pretreated/refractory to BTK inhibitors, and...
WORCESTER, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (Mustang or the Company) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical...
WORCESTER, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (Mustang or the Company) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical...
Mustang Bio axes 81% of staffers: The CAR-T cell therapy company plans to implement a workforce reduction throughout April to preserve cash in the second quarter. Mustang had 80 full-time employees as of the end of 2023, per an SEC filing. — Ayisha Sharma
Planning for proof-of concept Phase 1 investigator-sponsored clinical trial evaluating MB-106 CD20-targeted CAR T-cell therapy in autoimmune diseases is underway and expected to initiate in the fourth...
Mustang Bio and City of Hope’s chimeric antigen receptor T-cell (CAR-T) therapy for recurrent glioblastoma resulted in stable disease or better in half of the subjects in a phase 1 clinical trial, including one patient whose cancer has not recurred for more than five years.
Mustang Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
Mustang Bio Announces Publication of Data from Phase 1 Evaluating